Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,000 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 43,000 F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10 | Direct | 16,900 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900 F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date October 31, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 223,993 |
Reported balance
Holding disclosure · report date 2023-10-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 223,993 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2020 Filed Aug 17, 2020 20:33 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 7,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-20-000004 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,796 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 50% on August 25, 2021, and 50% on August 25, 2022. Read SEC document |
| February 12, 2020 Filed Feb 12, 2020 23:28 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 4,354 | $19.73 | $85,914.87 |
DisclosureSEC source: 0001770252-20-000002 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,150 Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 22:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 591 | $28.63 | $16,920.33 |
DisclosureSEC source: 0001770252-19-000006 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,504 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 22:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 591 | $28.63 | $16,920.33 |
DisclosureSEC source: 0001770252-19-000006 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,095 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-19-000004 · edgardoc.xml · nonDerivative · entry 4 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,686 F2 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 26, 2020, 25% on September 26, 2021, 25% on September 26, 2022, and 25% on September 26, 2023. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 628 | $29.93 | $18,796.04 |
DisclosureSEC source: 0001770252-19-000004 · edgardoc.xml · nonDerivative · entry 3 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,686 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 628 | $29.93 | $18,796.04 |
DisclosureSEC source: 0001770252-19-000004 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,314 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 13 | $29.93 | $389.09 |
DisclosureSEC source: 0001770252-19-000004 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,942 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.